Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...

The European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI ...

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...

Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and paediatric patients. The drug has been specifically authorised for the ...

In his new role, Dr. Boshoff wi NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI ...

Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of bleeding episodes in patients 12 years of age and older ...

HYMPAVZI is a once-weekly subcutaneous treatment option for individuals with severe haemophilia A or B. Credit: Andrey_Popov/Shutterstock. The European Commission (EC ...

(RTTNews) - Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI (marstacimab) to treat adults and adolescents with ...